Nanotherapeutics awarded two BARDA task orders

Nanotherapeutics Inc. received two task orders to fill development needs for Food and Drug Administration (FDA) prescription shortages from the U.S. Biomedical Advanced Research and Development Authority (BARDA), the company announced Thursday.

These orders have the potential to serve the FDA and the Department of Health and Human Services (HHS) to mitigate shortages of critical medications and other treatments that have little or no availability in the current pharmaceutical market. The task orders awarded to the company in the last 18 months included the process of validation through the FDA.

If the company is successful in development of the drugs and if they receive FDA and Center for Drug Evaluation and Research (CDER) approval, they could be used to increasing fill and finishing manufacturing capacity for each respective product.

In 2013, BARDA established the Fill-Finish Manufacturing Network (FFMN) to address the need of production and clinical investigations for various medical conditions and to facilitate the national ability to produce vaccines for influenza in the case of a pandemic. During that time, the company was awarded four task orders to meet the need of mass influenza vaccine production and the production of other health emergency products.

Organizations in this Story

Nanotherapeutics, Inc

Want to get notified whenever we write about Nanotherapeutics, Inc ?
Next time we write about Nanotherapeutics, Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.